Scarica l'app Stockscreener
44.74
2.31%
-1.06
Dopo l'orario di chiusura:
44.47
-0.27
-0.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$45.80
Aprire:
$45.4
Volume 24 ore:
16.36M
Relative Volume:
0.83
Capitalizzazione di mercato:
$198.33B
Reddito:
$50.91B
Utile/perdita netta:
$18.95B
Rapporto P/E:
10.50
EPS:
4.261
Flusso di cassa netto:
$1.92B
1 W Prestazione:
-2.89%
1M Prestazione:
+9.63%
6M Prestazione:
-7.29%
1 anno Prestazione:
-32.37%
Intervallo 1D:
$44.25
$45.50
Intervallo di 1 settimana:
$44.25
$47.79
Portata 52W:
$35.12
$81.44
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVO vs LLY, JNJ, ABBV, NVS, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
44.74 | 203.02B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,004.92 | 897.72B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
226.71 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
210.39 | 372.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
148.08 | 285.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
181.58 | 286.84B | 60.48B | 10.40B | 8.05B | 3.3297 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2026-03-18 | Iniziato | Bernstein | Outperform |
| 2026-03-10 | Downgrade | TD Cowen | Buy → Hold |
| 2026-03-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Downgrade | Goldman | Buy → Neutral |
| 2026-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Downgrade | Kepler | Buy → Hold |
| 2026-02-23 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Aggiornamento | Jefferies | Underperform → Hold |
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2025-12-08 | Downgrade | Argus | Buy → Hold |
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Is Kailera Therapeutics a Buy After Its Sizzling IPO? - The Motley Fool
Novo Nordisk A/S stock (DK0062498333): weight-loss demand drives fresh guidance upgrade - AD HOC NEWS
Novo Nordisk A/S stock (DK0062498333): Wegovy data and earnings outlook keep GLP-1 race in focus - AD HOC NEWS
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk Highlights New Wegovy Pill Data - Sahm
NVO Technical Analysis | Trend, Signals & Chart Patterns | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk A/ S stock (DK0060534915): Up 1.29% to $47 amid recovery trend - AD HOC NEWS
Novo Nordisk Oral Wegovy Data Sharpen Obesity Opportunity And Valuation Gap - Sahm
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Novo Nordisk A/ S stock (DK0062498333): Wegovy data fuels 3% premarket surge - AD HOC NEWS
Amazon Pharmacy Deal Puts Novo Nordisk Access And Valuation In Focus - Sahm
Novo Nordisk A/S stock (DK0060534915): Weight-loss and diabetes leader faces new pricing pressures - AD HOC NEWS
Novo Nordisk A/S stock (DK0062498333): Q1 beats and 2026 outlook lift shares on Nasdaq Copenhagen an - AD HOC NEWS
Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook - Sahm
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 15 Years - Sahm
Market news - investments.halifax.co.uk
Shares in Novo Nordisk jump after Wegovy pill sales smash forecasts - Sharecast.com
Novo Nordisk Explores New Growth In Alcohol Use Disorder And Obesity - Sahm
FDA Proposal Could Support Novo Nordisk GLP‑1 Exclusivity And Valuation - Sahm
European ADRs Jumped In US Trading, Led By Novo Nordisk - Finimize
Novo Nordisk’s Oral Ozempic And Pediatric Plans Reframe GLP-1 Opportunity - Sahm
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus
Novo Nordisk (NYSE: NVO) details DKK 3.4B B-share repurchases - Stock Titan
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients - Sahm
NVO Stock Price, Quote & Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
US-Listed European ADRs Slipped As Drugmakers Weighed On The Tape - Finimize
Novo Nordisk A/S stock (DK0062498333): Is its obesity drug dominance strong enough to sustain long-t - AD HOC NEWS
[6-K] NOVO NORDISK A S Current Report (Foreign Issuer) | NVO SEC FilingForm 6-K - Stock Titan
Novo Nordisk A/S stock (DK0062498333): Is obesity drug dominance strong enough to unlock new upside? - AD HOC NEWS
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):